Islet Cell Therapies Take the Stage at Public Workshop
Islet cell therapies for type 1 diabetes (T1D) are in the works. In clinical trials, people are coming off external insulin—and experiencing healthy blood sugar levels. Researchers and clinicians are working hard behind the scenes to advance next-generation manufactured islet cell therapies as scalable cures. The momentum is real—and it’s more important than ever to […]
Finerenone Approved for Chronic Kidney Disease Associated With T1D
Finerenone is the First Therapy Approved in 30 Years for Kidney Disease and T1D Today, the U.S. Food and Drug Administration (FDA) approved finerenone (brand name Kerendia) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). UACR is a measure of kidney damage, and reducing […]
Publication Alert: T1D Screening Consensus Guidance is Here
New Publication Alert! Breakthrough T1D spearheaded a paper titled “International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes” that was published in Diabetologia. This is an important step toward integrating general population screening for type 1 diabetes (T1D) into clinical practice globally. Read on to learn more about […]
Changing the Diagnosis Story: Building Solutions for T1D Risk Screening
This article was written by Francine Maloney, MPH (Director, Implementation and Director, U.S. Coalition for Early T1D Action) and Umila Singh, MFA (Design Specialist, Innovation) from Ariadne Labs at Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health. The U.S. Coalition for Early T1D Action has utilized our Participant Advisory Council (PAC) […]
New Publication: Sana’s Gene-Edited Islets Continue to Make Insulin
What’s Happening? A new publication in The New England Journal of Medicine provides more detail about the first person with type 1 diabetes (T1D) treated with Sana Biotechnology’s gene-edited islets. This person is still making insulin 14+ months after their islet transplant—without immunosuppressants! What to Know About Sana’s Gene-Edited Islets Sana’s novel cell therapy approach […]
From T1D Toddler to Resilient Adult: Jessie Stover Shares her Story
Spotlight on Jessie Stover Jessie Stover is the Development Manager at Breakthrough T1D’s Indiana Chapter. Stover was born and raised in Evansville, Indiana, and she now lives in Indianapolis with her two cats, Milo and Zuko. She enjoys reading, crafting, concerts, and “baking gluten-free desserts so good that no one can tell they’re gluten-free.” Here, […]
Could Drugs Like Ozempic also Benefit People with Type 1 Diabetes?
Learn more about GLP-1 therapies and SGLT inhibitors, and how drugs like Ozempic may one day be able to help people with type 1 diabetes.
Tzield Approved for Stage 3 T1D in the U.S.
What’s Happening? In an exciting update for the type 1 diabetes (T1D) community, Tzield—the first disease-modifying therapy approved by the FDA to delay progression of stage 2 T1D—has now been approved by the FDA for use in stage 3 T1D. People aged 8-17 with stage 3 T1D will soon be able to get Tzield in clinics (with a prescription) if […]
Everything you need to know about ADA 2026
Breakthrough T1D was on site in New Orleans, LA from June 5-8 for the American Diabetes Association’s (ADA) 86th Scientific Sessions. Check out all of our coverage below, including type 1 diabetes (T1D) advances across all our mission priority areas and several Breakthrough T1D-funded researchers and staff driving progress forward. In case you missed it, […]
Cell Therapy Clinical Trials: Breaking Down the Science
Breakthrough T1D is here to answer all of your questions about islet cell therapies, from the research lab to real-world treatments.
